For help on how to get the results you want, see our search tips.
754 results
Medicine
European public assessment reports (EPAR) Remove European public assessment reports (EPAR) filter
Withdrawn applications Remove Withdrawn applications filter
Categories
Human Remove Human filter
-
List item
Human medicine European public assessment report (EPAR): Xenpozyme (updated)
Olipudase alfa, Acid sphingomyelinase deficiency (ASMD) type A/B or type B
Date of authorisation: 24/06/2022,
, 
, Authorised, Last updated: 27/07/2022
-
List item
Human medicine European public assessment report (EPAR): Pemetrexed Fresenius Kabi (updated)
pemetrexed, Carcinoma, Non-Small-Cell Lung; Mesothelioma
Date of authorisation: 22/07/2016,
, Revision: 13, Authorised, Last updated: 27/07/2022
-
List item
Human medicine European public assessment report (EPAR): Vyxeos liposomal (previously known as Vyxeos) (updated)
daunorubicin hydrochloride, cytarabine, Leukemia, Myeloid, Acute
Date of authorisation: 23/08/2018,, Revision: 7, Authorised, Last updated: 27/07/2022
-
List item
Human medicine European public assessment report (EPAR): Grepid (updated)
clopidogrel (as besilate), Peripheral Vascular Diseases; Stroke; Myocardial Infarction
Date of authorisation: 27/07/2009,, Revision: 25, Authorised, Last updated: 27/07/2022
-
List item
Human medicine European public assessment report (EPAR): Wegovy (updated)
semaglutide, Obesity; Overweight
Date of authorisation: 06/01/2022,, Revision: 1, Authorised, Last updated: 26/07/2022
-
List item
Human medicine European public assessment report (EPAR): Zirabev (updated)
bevacizumab, Colorectal Neoplasms; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Uterine Cervical Neoplasms
Date of authorisation: 14/02/2019,, 
, Revision: 11, Authorised, Last updated: 26/07/2022
-
List item
Human medicine European public assessment report (EPAR): Granpidam (updated)
sildenafil citrate, Hypertension, Pulmonary
Date of authorisation: 14/11/2016,, Revision: 7, Authorised, Last updated: 26/07/2022
-
List item
Human medicine European public assessment report (EPAR): Rybelsus (updated)
semaglutide, Diabetes Mellitus, Type 2
Date of authorisation: 03/04/2020,, Revision: 4, Authorised, Last updated: 26/07/2022
-
List item
Human medicine European public assessment report (EPAR): Orgovyx (updated)
relugolix, Prostatic Neoplasms
Date of authorisation: 29/04/2022,, Revision: 3, Authorised, Last updated: 26/07/2022
-
List item
Human medicine European public assessment report (EPAR): Bavencio (updated)
avelumab, Neuroendocrine Tumors
Date of authorisation: 18/09/2017,, Revision: 13, Authorised, Last updated: 26/07/2022
-
List item
Human medicine European public assessment report (EPAR): Fintepla (updated)
Fenfluramine hydrochloride, Epilepsies, Myoclonic
Date of authorisation: 18/12/2020,, , Revision: 3, Authorised, Last updated: 26/07/2022
-
List item
Human medicine European public assessment report (EPAR): Vitrakvi (updated)
larotrectinib sulfate, Abdominal Neoplasms
Date of authorisation: 19/09/2019,, 
, Revision: 6, Authorised, Last updated: 26/07/2022
-
List item
Human medicine European public assessment report (EPAR): Ontruzant (updated)
trastuzumab, Stomach Neoplasms; Breast Neoplasms
Date of authorisation: 15/11/2017,, Revision: 13, Authorised, Last updated: 26/07/2022
-
List item
Human medicine European public assessment report (EPAR): Rhokiinsa (updated)
Netarsudil, Glaucoma, Open-Angle; Ocular Hypertension
Date of authorisation: 19/11/2019,, Revision: 2, Authorised, Last updated: 26/07/2022
-
List item
Human medicine European public assessment report (EPAR): Cablivi (updated)
Caplacizumab, Purpura, Thrombotic Thrombocytopenic
Date of authorisation: 30/08/2018,, , Revision: 6, Authorised, Last updated: 26/07/2022
-
List item
Human medicine European public assessment report (EPAR): Imfinzi (updated)
durvalumab, Carcinoma, Non-Small-Cell Lung
Date of authorisation: 21/09/2018,, Revision: 12, Authorised, Last updated: 26/07/2022
-
List item
Human medicine European public assessment report (EPAR): Ziextenzo (updated)
pegfilgrastim, Neutropenia
Date of authorisation: 22/11/2018,, , Revision: 5, Authorised, Last updated: 26/07/2022
-
List item
Human medicine European public assessment report (EPAR): Keytruda (updated)
Pembrolizumab, Melanoma; Hodgkin Disease; Carcinoma, Renal Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Transitional Cell; Squamous Cell Carcinoma of Head and Neck; Urologic Neoplasms; Endometrial Neoplasms
Date of authorisation: 17/07/2015,, Revision: 47, Authorised, Last updated: 26/07/2022
-
List item
Human medicine European public assessment report (EPAR): Revestive (updated)
teduglutide, Malabsorption Syndromes
Date of authorisation: 30/08/2012,, , Revision: 20, Authorised, Last updated: 26/07/2022
-
List item
Human medicine European public assessment report (EPAR): Fotivda (updated)
tivozanib, Carcinoma, Renal Cell
Date of authorisation: 24/08/2017,, Revision: 8, Authorised, Last updated: 25/07/2022
-
List item
Human medicine European public assessment report (EPAR): Uplizna (updated)
Inebilizumab, Neuromyelitis Optica
Date of authorisation: 25/04/2022,, Revision: 1, Authorised, Last updated: 25/07/2022
-
List item
Human medicine European public assessment report (EPAR): Orkambi (updated)
Lumacaftor, ivacaftor, Cystic Fibrosis
Date of authorisation: 18/11/2015,, Revision: 29, Authorised, Last updated: 25/07/2022
-
List item
Human medicine European public assessment report (EPAR): Trelegy Ellipta (updated)
fluticasone furoate, umeclidinium bromide, vilanterol trifenatate, Pulmonary Disease, Chronic Obstructive
Date of authorisation: 15/11/2017,, Revision: 9, Authorised, Last updated: 25/07/2022
-
List item
Human medicine European public assessment report (EPAR): Mayzent (updated)
Siponimod fumaric acid, Multiple Sclerosis, Relapsing-Remitting
Date of authorisation: 13/01/2020,, Revision: 8, Authorised, Last updated: 25/07/2022
-
List item
Human medicine European public assessment report (EPAR): Elebrato Ellipta (updated)
fluticasone furoate, umeclidinium bromide, vilanterol trifenatate, Pulmonary Disease, Chronic Obstructive
Date of authorisation: 15/11/2017,, Revision: 10, Authorised, Last updated: 25/07/2022